We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01131546
First Posted: May 27, 2010
Last Update Posted: June 1, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Jiangsu Simcere Pharmaceutical Co., Ltd.
May 25, 2010
May 27, 2010
June 1, 2011
December 2009
March 2011   (Final data collection date for primary outcome measure)
Proportion of patients who reach overall blood pressure control (defined as BP <140/90 mmHg for non-diabetic patients and < 130/80 mmHg for diabetic patients) [ Time Frame: Week 8 ]
Same as current
Complete list of historical versions of study NCT01131546 on ClinicalTrials.gov Archive Site
  • Change from baseline in systolic blood pressure (SBP) [ Time Frame: Week 8 ]
  • Change from baseline in diastolic blood pressure (DBP) [ Time Frame: Week 8 ]
  • Incidence of adverse effects [ Time Frame: 8 weeks ]
Same as current
Not Provided
Not Provided
 
Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension
A Randomized, Controlled, Multicenter Trial of Levamlodipine Besylate Versus Amlodipine Maleate in Patients With Essential Hypertension
This study is designed to compare the safety and efficacy of levamlodipine besylate (2.5mg or 5mg) versus amlodipine maleate (5mg) in patients with mild to moderate essential hypertension.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Essential Hypertension
  • Drug: Levamlodipine besylate
    Once daily, 7AM - 10AM
  • Drug: Amlodipine maleate
    Once daily, 7AM - 10AM
  • Experimental: Levamlodipine besylate (2.5mg)
    Intervention: Drug: Levamlodipine besylate
  • Experimental: Levamlodipine besylate (5mg)
    Intervention: Drug: Levamlodipine besylate
  • Active Comparator: Amlodipine maleate (5mg)
    Intervention: Drug: Amlodipine maleate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1080
March 2011
March 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female outpatients, 18-75 Years
  • Patients with mild to moderate essential hypertension (defined as mean BP of 2 visits ≥140mm/90mmHg, and < 180mm/110mmHg)
  • Written informed consent

Exclusion Criteria:

  • Patients with secondary hypertension
  • Patients with severe hypertension
  • Have to take other drugs that can influence blood pressure during the study
  • Allergic to DHP calcium antagonists
  • Evidence of congestive heart failure, unstable angina or severe arrhythmia
  • Renal or hepatic dysfunction
  • Women who are taking contraceptive pills or are likely to be pregnant
  • Participate in other clinical trials within 3 months prior to this study
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT01131546
SIM-77
No
Not Provided
Not Provided
Jinsheng Ren, Jiangsu Simcere Pharmaceutical R&D Co. Ltd.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Not Provided
Principal Investigator: Dayi Hu, MD Peking University People's Hospital
Principal Investigator: Jinming Yu, Ph.D. School of Public Health, Fudan University
Jiangsu Simcere Pharmaceutical Co., Ltd.
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP